The changing landscape of HIV-related lung disease: non-AIDS lung malignancy as a player in the field.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Decreased Lung Function and All-Cause Mortality in HIV-infected Individuals.Annals of the American Thoracic Society · 2018
   Trial
2. HealthMap: a cluster randomised trial of interactive health plans and self-management support to prevent coronary heart disease in people with HIV.BMC infectious diseases · 2016
   Trial
3. The systematic development of a complex intervention: HealthMap, an online self-management support program for people with HIV.BMC infectious diseases · 2018
   Article

Corrections and comments

• Comment on
  High prevalence of malignancy in HIV-positive patients with mediastinal lymphadenopathy: a study in the era of antiretroviral therapy.2014

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as